Compare CVLG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLG | ESPR |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.1M | 731.9M |
| IPO Year | 1996 | 2013 |
| Metric | CVLG | ESPR |
|---|---|---|
| Price | $28.47 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 107.4K | ★ 5.6M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $705,007,000.00 | $403,135,000.00 |
| Revenue This Year | $7.17 | $1.53 |
| Revenue Next Year | $7.53 | N/A |
| P/E Ratio | $106.78 | ★ N/A |
| Revenue Growth | 5.12 | ★ 21.31 |
| 52 Week Low | $17.46 | $0.73 |
| 52 Week High | $30.43 | $4.18 |
| Indicator | CVLG | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 30.66 |
| Support Level | $22.52 | $1.02 |
| Resistance Level | $30.33 | $2.08 |
| Average True Range (ATR) | 0.86 | 0.20 |
| MACD | 0.22 | -0.03 |
| Stochastic Oscillator | 76.97 | 1.76 |
Covenant Logistics Group Inc together with its wholly-owned subsidiaries, offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight, and Warehousing. The expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. The Managed Freight segment includes brokerage services and TMS. The warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.